MRK and MRNA Related Headlines
Go Back- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Guggenheim Reiterates Buy Rating on Merck (MRK)
- Moderna (MRNA) PT Raised to $89 at Morgan Stanley
- Morgan Stanley Upgrades Merck (MRK) to Overweight
- William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
- Moderna shares soar on melanoma drug trial success
- Merck and Moderna's melanoma drug combo beats Keytruda alone in trial
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wi
- Trump Administration Weighs Order On Autism And Vaccines - Bloomberg
- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- Moderna and Merck report sustained melanoma treatment benefits at 5 years
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
- US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
- This U.S. biotech stock is Bernstein's Top Pick for 2026
- Moderna and Merck report sustained melanoma treatment benefits at 5 years
- Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
- Vaccine stocks brace for shock waves at this week’s ACIP meeting
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
MRK and MRNA Related Press Releases
Go Back- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wi
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
- Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
